Shares of Prometheus Biosciences, Inc. (NASDAQ:RXDX) have received a consensus rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.60.
RXDX has been the topic of a number of recent analyst reports. SVB Leerink boosted their price target on shares of Prometheus Biosciences from $34.00 to $43.00 and gave the stock an “outperform” rating in a research note on Monday, November 15th. Zacks Investment Research lowered shares of Prometheus Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, November 18th. Stifel Nicolaus assumed coverage on shares of Prometheus Biosciences in a research report on Friday, November 12th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Oppenheimer lowered shares of Prometheus Biosciences from an “outperform” rating to a “market perform” rating and set a $35.00 target price on the stock. in a research report on Monday, November 15th.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in shares of Prometheus Biosciences by 7.8% during the third quarter. Bank of New York Mellon Corp now owns 33,854 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 2,450 shares during the period. Laurion Capital Management LP grew its holdings in Prometheus Biosciences by 171.9% during the 3rd quarter. Laurion Capital Management LP now owns 168,798 shares of the biopharmaceutical company’s stock valued at $4,003,000 after purchasing an additional 106,714 shares in the last quarter. Metropolitan Life Insurance Co NY acquired a new stake in Prometheus Biosciences during the 3rd quarter valued at $88,000. CHI Advisors LLC boosted its stake in Prometheus Biosciences by 0.4% during the 3rd quarter. CHI Advisors LLC now owns 2,862,059 shares of the biopharmaceutical company’s stock valued at $67,859,000 after acquiring an additional 10,050 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its stake in Prometheus Biosciences by 2.4% during the 3rd quarter. Rock Springs Capital Management LP now owns 610,136 shares of the biopharmaceutical company’s stock valued at $14,466,000 after acquiring an additional 14,040 shares during the last quarter. 61.20% of the stock is currently owned by institutional investors.
Prometheus Biosciences (NASDAQ:RXDX) last released its quarterly earnings data on Thursday, November 11th. The biopharmaceutical company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.11). As a group, research analysts expect that Prometheus Biosciences will post -2.14 earnings per share for the current fiscal year.
Prometheus Biosciences Company Profile
Prometheus Biosciences, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD.
Receive News & Ratings for Prometheus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prometheus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.